Gastric cancer (GC) is one of the most malignant human cancers with increasing incidence
worldwide, ranking among the top five malignant tumors worldwide in terms of incidence …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Simple Summary Gastric cancer is the fifth most common tumor worldwide. In the past
couple of decades, there have been many advancements toward earlier detection and better …

Gastric cancer, the fifth most frequent cancer and the fourth leading cause of cancer deaths,
accounts for a devastating death rate worldwide. Since the majority of patients with gastric …

Background This study reports the 2-year outcomes and biomarker analysis results of
patients with locally advanced gastric and gastroesophageal junction (G/GEJ) …

Simple Summary Biomarker research for immunotherapy in gastroesophageal cancer has
been rapidly developing in parallel with the growing use of immune checkpoint inhibitors …

Objective To explore the oncological outcomes of sequential laparoscopic gastrectomy after
treatment with camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of …

Methods We conducted an extensive review of immunotherapy articles in the PubMed
database between December 2013 and October 2021. Articles in English were included. We …

Objective To investigate the safety and efficacy of camrelizumab in combination with nab-
paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion. Method Two …

Background Neoadjuvant chemotherapy with S-1 plus oxaliplatin (SOX regimen) has shown
promising results in pathological response rate and survival rate in patients with locally …